SOLU CORTEF

Solu Cortef Adverse Events Reported to the FDA Over Time

How are Solu Cortef adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Solu Cortef, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Solu Cortef is flagged as the suspect drug causing the adverse event.

Most Common Solu Cortef Adverse Events Reported to the FDA

What are the most common Solu Cortef adverse events reported to the FDA?

Dyspnoea	45 (1.93%)
Shock	42 (1.8%)
Anaphylactic Shock	33 (1.42%)
Pyrexia	32 (1.37%)
Pneumonia	27 (1.16%)
Drug Ineffective	24 (1.03%)
Nausea	24 (1.03%)
Urticaria	24 (1.03%)
Hypotension	22 (.94%)
Hypersensitivity	21 (.9%)
Respiratory Failure	21 (.9%)
	Show More
Reversible Posterior Leukoencephalo...	21 (.9%)
Convulsion	20 (.86%)
Infusion Related Reaction	20 (.86%)
Blood Glucose Increased	19 (.82%)
Flushing	18 (.77%)
Loss Of Consciousness	18 (.77%)
Vomiting	18 (.77%)
Blood Pressure Decreased	17 (.73%)
Blood Pressure Increased	17 (.73%)
Septic Shock	17 (.73%)
Anaemia	16 (.69%)
Condition Aggravated	16 (.69%)
Diarrhoea	16 (.69%)
Platelet Count Decreased	16 (.69%)
Anaphylactic Reaction	15 (.64%)
Asthma	15 (.64%)
Malaise	13 (.56%)
Abdominal Pain	12 (.51%)
Disorientation	12 (.51%)
Hyperglycaemia	12 (.51%)
Hyperhidrosis	12 (.51%)
Osteonecrosis	12 (.51%)
Pleural Effusion	12 (.51%)
Stevens-johnson Syndrome	12 (.51%)
Acute Respiratory Distress Syndrome	11 (.47%)
Agitation	11 (.47%)
Deep Vein Thrombosis	11 (.47%)
Erythema	11 (.47%)
Pulmonary Oedema	11 (.47%)
Tachycardia	11 (.47%)
Thrombocytopenia	11 (.47%)
Cough	10 (.43%)
Febrile Neutropenia	10 (.43%)
Hypertension	10 (.43%)
Infection	10 (.43%)
Paraesthesia	10 (.43%)
Renal Failure Acute	10 (.43%)
Sepsis	10 (.43%)
Adrenocortical Insufficiency Acute	9 (.39%)
Dysphagia	9 (.39%)
Heparin-induced Thrombocytopenia	9 (.39%)
Hepatic Function Abnormal	9 (.39%)
Histiocytosis Haematophagic	9 (.39%)
Hypokalaemia	9 (.39%)
Oedema	9 (.39%)
Pruritus	9 (.39%)
Ventricular Extrasystoles	9 (.39%)
Anaphylactoid Reaction	8 (.34%)
Aspartate Aminotransferase Increase...	8 (.34%)
Blood Lactic Acid Decreased	8 (.34%)
Blood Pressure Systolic Increased	8 (.34%)
Dehydration	8 (.34%)
Gastrointestinal Haemorrhage	8 (.34%)
Hepatosplenomegaly	8 (.34%)
Hypoaesthesia	8 (.34%)
Leukopenia	8 (.34%)
Medication Error	8 (.34%)
Multi-organ Failure	8 (.34%)
Muscular Weakness	8 (.34%)
Pain	8 (.34%)
Pancytopenia	8 (.34%)
Alanine Aminotransferase Increased	7 (.3%)
Breath Sounds Abnormal	7 (.3%)
Cardiomegaly	7 (.3%)
Chest Discomfort	7 (.3%)
Delirium	7 (.3%)
Depressed Level Of Consciousness	7 (.3%)
Disseminated Intravascular Coagulat...	7 (.3%)
Epstein-barr Virus Infection	7 (.3%)
Erythema Multiforme	7 (.3%)
Gastroenteritis	7 (.3%)
Grand Mal Convulsion	7 (.3%)
Headache	7 (.3%)
Hypophagia	7 (.3%)
Klebsiella Infection	7 (.3%)
Liver Function Test Abnormal	7 (.3%)
Lung Infiltration	7 (.3%)
Mental Status Changes	7 (.3%)
Myalgia	7 (.3%)
Neutropenia	7 (.3%)
Pharyngeal Oedema	7 (.3%)
Rash	7 (.3%)
Respiratory Distress	7 (.3%)
Rhabdomyolysis	7 (.3%)
Sinus Bradycardia	7 (.3%)
Syncope	7 (.3%)
Tremor	7 (.3%)
Tuberculosis	7 (.3%)
Upper Respiratory Tract Infection	7 (.3%)
Vision Blurred	7 (.3%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Solu Cortef, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Solu Cortef is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Solu Cortef

What are the most common Solu Cortef adverse events reported to the FDA?

Infections - Pathogen Unspecified	128 (5.49%)
Respiratory	107 (4.59%)
Neurological	95 (4.08%)
Epidermal And Dermal Conditions	90 (3.86%)
Allergic Conditions	87 (3.73%)
Gastrointestinal Signs	78 (3.35%)
Decreased And Nonspecific Blood Pre...	66 (2.83%)
Cardiac And Vascular Investigations	64 (2.75%)
Cardiac Arrhythmias	63 (2.7%)
Hematology Investigations	45 (1.93%)
Hepatic And Hepatobiliary	39 (1.67%)
	Show More
Metabolic, Nutritional And Blood Ga...	37 (1.59%)
Body Temperature Conditions	36 (1.54%)
Hepatobiliary	36 (1.54%)
Lower Respiratory Tract Disorders	36 (1.54%)
Therapeutic And Nontherapeutic Effe...	35 (1.5%)
Bronchial Disorders	32 (1.37%)
Bacterial Infectious	31 (1.33%)
Electrolyte And Fluid Balance Condi...	30 (1.29%)
Muscle	30 (1.29%)
White Blood Cell	29 (1.24%)
Angiedema And Urticaria	28 (1.2%)
Seizures	28 (1.2%)
Vascular	27 (1.16%)
Administration Site Reactions	26 (1.12%)
Gastrointestinal Hemorrhages	25 (1.07%)
Physical Examination Topics	25 (1.07%)
Anemias Nonhemolytic And Marrow Dep...	24 (1.03%)
Fungal Infectious	24 (1.03%)
Glucose Metabolism Disorders	24 (1.03%)
Movement Disorders	24 (1.03%)
Deliria	23 (.99%)
Encephalopathies	23 (.99%)
Viral Infectious	22 (.94%)
Platelet	21 (.9%)
Medication Errors	20 (.86%)
Renal Disorders	20 (.86%)
Adrenal Gland	19 (.82%)
Anxiety Disorders	19 (.82%)
Gastrointestinal Motility And Defec...	18 (.77%)
Upper Respiratory Tract Disorders	18 (.77%)
Myocardial	17 (.73%)
Skin Appendage Conditions	16 (.69%)
Bone Disorders	15 (.64%)
Mycobacterial Infectious	14 (.6%)
Pleural	14 (.6%)
Procedural And Device Related Injur...	14 (.6%)
Urinary Tract Signs	14 (.6%)
Appetite And General Nutritional	13 (.56%)
Embolism And Thrombosis	13 (.56%)
Injuries	13 (.56%)
Coagulopathies And Bleeding Diathes...	12 (.51%)
Gastrointestinal Ulceration And Per...	12 (.51%)
Respiratory Tract Therapeutic Proce...	12 (.51%)
Coronary Artery	11 (.47%)
Immune	11 (.47%)
Vascular Hypertensive	11 (.47%)
Vision	11 (.47%)
Gastrointestinal Conditions	10 (.43%)
Headaches	10 (.43%)
Hematopoietic Neoplasms	10 (.43%)
Musculoskeletal And Connective Tiss...	10 (.43%)
Neuromuscular	10 (.43%)
Enzyme	9 (.39%)
Miscellaneous And Site Unspecified ...	9 (.39%)
Psychiatric	9 (.39%)
Eye	8 (.34%)
Bone And Joint Injuries	7 (.3%)
Cardiac Disorder Signs	7 (.3%)
Acid-base	6 (.26%)
Disturbances In Thinking	6 (.26%)
Exocrine Pancreas Conditions	6 (.26%)
Hematological And Lymphoid Tissue T...	6 (.26%)
Immunodeficiency Syndromes	6 (.26%)
Joint	6 (.26%)
Leukemias	6 (.26%)
Manic And Bipolar Mood Disorders	6 (.26%)
Ocular Infections, Irritations And ...	6 (.26%)
Oral Soft Tissue Conditions	6 (.26%)
Protein And Amino Acid Metabolism	6 (.26%)
Renal And Urinary Tract Investigati...	6 (.26%)
Spinal Cord And Nerve Root	6 (.26%)
Chemical Injury And Poisoning	5 (.21%)
Heart Failures	5 (.21%)
Therapeutic Procedures And Supporti...	5 (.21%)
Bone, Calcium, Magnesium And Phosph...	4 (.17%)
Endocrine Neoplasms Malignant And U...	4 (.17%)
Fatal Outcomes	4 (.17%)
Increased Intracranial Pressure And...	4 (.17%)
Microbiology And Serology	4 (.17%)
Neonatal And Perinatal Conditions	4 (.17%)
Peritoneal And Retroperitoneal Cond...	4 (.17%)
Sleep Disorders	4 (.17%)
Water, Electrolyte And Mineral	4 (.17%)
Anal And Rectal Conditions	3 (.13%)
Central Nervous System Vascular	3 (.13%)
Changes In Physical Activity	3 (.13%)
Communication Disorders	3 (.13%)
Gastrointestinal Inflammatory Condi...	3 (.13%)
Hemolyses And Related Conditions	3 (.13%)
Hypothalamus And Pituitary Gland	3 (.13%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Solu Cortef, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Solu Cortef is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.